Company Report
Last edited 2 years ago
PerformanceCommunity EngagementCommunity Endorsement
ranked
#112
Performance (45m)
1.2% pa
Followed by
11
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#Media release
stale
Added 2 years ago

An update from PIQ this morning from a recent conference. Essentially showing the blood test they have been developing as a screening test for endometriosis is is 90% effective at detecting endometriosis.

Important to note that the study was comparing no disease Vs endoscopically confirmed severe disease. However this is still a promising step forwards. Sensitivity was 89% (rules out) & specificity 95% (rules in). The test was reactive according to disease activity.

New-endometriosis-test-presented-at-international-conference.pdf

Currently, there is no diagnostic test, when a high level of suspicion is present and the symptoms are debilitating a diagnostic laparoscope is used to visualise endometrial tissue within the pelvic cavity (yet outside the uterus, which is the definition of the disease). The mainstay of treatment is NSAID pain relief for mild to moderate disease. For woman with more severe disease/ symptoms surgical intervention can be required. Important to note that this disease can severely affect fertility, and so can the treatments. In some cases surgical intervention is done in an effort to improve fertility efforts.

Next step would be for them to prove it can detect mild and moderate disease.

The most important thing would be to demonstrate how detecting the disease earlier would affect outcomes. Obviously earlier confirmation of diagnosis would assist in pain management, which is amazing for patients, however, I would argue that unless a new test actually changes the disease outcome via better interventions then this isn't going to reinvent the wheel.

Held on strawman (for the test for CKD, which earlier detection would improve outcomes because it is so insidious).

#Risks
stale
Added 2 years ago

This is exactly the question I want to ask them if we can arrange an interview. How will this new test alter practice, and therefor patient outcomes. It is positive that MSAC acknowledge that long term this test could save money (translation: improve patient outcomes and reduce morbidity and hospital admissions) but without a clear positive impact on whether it would alter current clinical care for chronic kidney disease (CKD) this is up in the air.


I would think it would alter care, earlier intervention, earlier and more aggressive prescribing of nephroprotective drugs, better informed care for patients who with this knowledge may alter lifestyle factors (which are nephrotoxic in many cases).


I hold on SM because the money isn't real. But following IRL

:)

dd7ff0c0fc5b85acae79e2323124c919d391c0.png